BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
79.37
-1.03 (-1.28%)
At close: Aug 26, 2026, 4:00 PM EDT
80.14
+0.77 (0.97%)
After-hours: Aug 26, 2026, 6:29 PM EDT

BridgeBio Pharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-691.87-724.93-535.76-643.2-481.18-562.54
Depreciation & Amortization
5.075.436.086.496.775.84
Other Amortization
6.665.977.468.91--
Loss (Gain) From Sale of Assets
---178.321.246.26-
Asset Writedown & Restructuring Costs
----12.72-
Loss (Gain) From Sale of Investments
2.3--8.14-18.318.22-29.91
Loss (Gain) on Equity Investments
52.7563.7831.18---
Stock-Based Compensation
147.22133.0295.8108.7191.5699.51
Other Operating Activities
131.85121.8928.933.39-91.92-6.43
Change in Accounts Receivable
-177.62-134.72-2.9715.3315.17-19.75
Change in Inventory
-36.89-25.31----
Change in Accounts Payable
1.0726.611.512.78-0.352.83
Change in Unearned Revenue
-9.24-11.4321.88-5.4415.26-
Change in Other Net Operating Assets
134.3293.7811.63-7.61-212.52
Operating Cash Flow
-434.37-445.91-520.73-527.72-419.49-497.93
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-1.02-1.1-0.93-1.31-4.82-13.25
Sale of Property, Plant & Equipment
----10-
Cash Acquisitions
-----13.65
Divestitures
---0.14-0.5--
Sale (Purchase) of Intangibles
-2.4-8.5-7.98--1.5-35
Investment in Securities
-33.63-17.244.1555.84339.47-166.23
Other Investing Activities
2.32.325.68-110-
Investing Cash Flow
-34.74-24.4960.7854.03453.15-200.83

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-875950--1,204
Long-Term Debt Repaid
--459-473.42--20.49-124.12
Net Debt Issued (Repaid)
601.42416476.58--20.491,080
Issuance of Common Stock
54.5134.15322.9459.228.0820.46
Repurchase of Common Stock
-228.8-62.5-7.53-6.88-1.56-204.75
Other Financing Activities
-29.09-28.35-43.5-0.80.84-158.95
Financing Cash Flow
398.05359.29748.46451.54-13.13736.45

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
-71.06-111.1288.51-22.1520.5237.69

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-435.39-447.01-521.66-529.03-424.32-511.18
Free Cash Flow Growth
------
Free Cash Flow Margin
-61.06%-89.03%-235.08%-5686.62%-546.46%-733.23%
Free Cash Flow Per Share
-2.24-2.33-2.80-3.25-2.88-3.54
Levered Free Cash Flow
-320.26-325.29-291.12-240.16-285.88-301.13
Unlevered Free Cash Flow
-198.23-219.86-236.53-198.26-235.61-271.89

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
40.7243.6791.3461.1154.4429.77
Cash Income Tax Paid
1.21.2----
Change in Working Capital
-88.35-51.0632.045.0628.08-4.4
SEC Filings: 10-K · 10-Q